Skip to main content

Table 2 Summary of the HGF promoter sequencing

From: Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients

Patient no.

SNP (NCBI dbSNP)

INDEL mutation

NCBI dbSNP

DATE length

Sequence region

HGF Serum levels

MM 4

−1652C/T

Rs3735520

27

−2920 – +120

High

MM 5

−2142C/A

Rs11763015

26

−2870 – +120

High

−1652C/T

Rs3735520

MM 7

−2142C/A

Rs11763015

22

−2910 – -20

High

−1652C/T

Rs3735520

MM 14

2309 T/A*

Rs149178895*

29

−2920 – +120

High

−1652C/T

Rs3735520

MM 22

 

15

−2280 – +120

High

MM 24

Rs3735520

28

−2870 – +120

High

−1652C/T

MM 29

−1652C/T

Rs3735520

27

−2870 – +120

High

MM 3

−1652C/T

Rs3735520

22

−2870 – +120

Low

MM 12

−2142C/A

Rs11763015

22

−2840 – -1710

Low

MM 16

−1652C/T

Rs3735520

23

−2810 – +120

Low

MM 17

−1652C/T

Rs3735520

26

−2730 – +120

Low

MM 23

−2142C/A

Rs11763015

25

−2870 – +120

Low

 

−1652C/T

 

Rs3735520

   
  1. Genomic DNA isolates from CD138+ cells were used to amplify segments of the HGF promoter. PCR products were pre-treated with exonuclease I and shrimp alkaline phosphatase and directly used for Sanger DNA sequencing. RefSeq gene NG_016274 was used as reference sequence. SNP and sequence region are relative to transcription start site.
  2. SNP positions Rs3735520 and Rs11763015 are depicted relative to transcription start site (NM_000601.4:c).
  3. *SNP position RS149178895 is depicted relative to gene region NG_016274.1.